Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coherus: Ophthalmologists Have Been ‘Burned Time And Again’

Firm ‘Pleased And Confident’ With ‘Non-Core’ Lucentis Biosimilar, Cimerli

Executive Summary

Coherus BioSciences revealed that it has shipped nearly 200,000 doses of its Lucentis biosimilar Cimerli, as it pondered from where to grab further market share in 2024 at the J.P. Morgan Annual Healthcare Conference.

You may also be interested in...



Sandoz Plugs Ophthalmology Gap With Coherus Ranibizumab Deal

Sandoz has truly spread its wings since separating from Novartis, striking its first post-spinoff acquisition agreement by taking the Lucentis biosimilar Cimerli from Coherus BioSciences, which is moving in a different strategic direction.

Coherus Queries Higher Dose Aflibercept Amid Biosimilar Eylea Deal

Coherus BioSciences is feeling bullish about its potential in the biosimilar ophthalmology space after agreeing to bring on board a biosimilar Eylea (aflibercept) candidate, with an eye on launching potentially in 2025.

Emboldened In Court, Lupin Launches First US Oracea Generic At Risk

Lupin has shown its confidence in its legal position after introducing the first US generic version of Galderma’s rosacea treatment, Oracea, while the originator battles for injunctive relief.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153214

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel